LivaNova PLC
NASDAQ:LIVNMedical - Devices
+$0.76 today
- Market cap
- $5.21B
- Beta
- 0.88
- P/E (TTM)
- 40.5
- EPS (TTM)
- $1.96
Volume 1.32M
Average 0.79M
LIVN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
LivaNova PLCNASDAQ: LIVN
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures grows, but more slowly than its trailing trend
Q3 FY2026 capital expenditures of $30.8M (cash outflow) rose 34.6% year over year, behind the +83.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at +45.2% a year.
Context
- Capital expenditures amounted to 5.8% of revenue in FY2025, up 2.1 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +34.6% toward the trailing-twelve-month pace of +83.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (81.1M) USD
- Year-over-year change
- -72.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.1M) | -72.2% |
| FY2024 | 2024-12-31 | (47.11M) | -34.7% |
| FY2023 | 2023-12-31 | (34.98M) | -32.0% |
| FY2022 | 2022-12-31 | (26.5M) | -4.0% |
| FY2021 | 2021-12-31 | (25.48M) | — |
Capital Expenditures vs competitors
How LIVN compares with its peers on the latest reported figures
- LIVN's LTM Sep 2026 capital expenditures of $108.84M is the 5th largest of the 10 companies compared; the peer median is $39.98M.
- Its year-over-year change of +83.8% is the 2nd highest of 10, against a peer median of +5.4%.
- Capital expenditures amounts to 7.2% of revenue for LIVN, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.9B | +3.3% | +9.3% | 5.1% | |
| LTM Jun 2026 | $904M | -7.2% | +12.7% | 4.3% | |
| LTM Jun 2026 | $286.7M | +53.3% | -0.6% | 4.4% | |
| LTM Jun 2026 | $267.46M | +188.0% | +5.3% | 4.7% | |
| LTM Sep 2026 | $108.84M | +83.8% | +45.2% | 7.2% | |
| LTM Jun 2026 | $39.98M | +23.3% | +61.8% | 4.4% | |
| LTM Jun 2026 | $36.93M | -1.2% | -33.2% | 2.7% | |
| LTM Mar 2026 | $779K | -40.5% | -37.4% | 0.5% | |
| LTM Mar 2026 | $588K | +5.4% | -5.4% | 1.0% | |
| LTM Mar 2026 | $412K | +72.4% | -18.0% | 0.4% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LIVN) | $39.98M | +5.4% | -0.6% | 4.3% | |
Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (135.82M) | (86.2M) | 17.55M | 63.23M | (242.5M) |
| Depreciation & Amortization | 67.99M | 57.8M | 60.86M | 51.14M | 42M |
| Deferred Income Tax | 2.85M | 1.4M | (114.43M) | 6.8M | 500K |
| Stock-Based Compensation | 40.56M | 44.81M | 36.35M | 33.93M | 36.3M |
| Change in Working Capital | 29.22M | (31.7M) | (34.62M) | 1.31M | 369.97M |
| Accounts Receivables | (15.75M) | (4.8M) | (28.86M) | 11.1M | (10.7M) |
| Inventory | 4.48M | (25.7M) | (28.48M) | (6.8M) | (5.3M) |
| Accounts Payables | 12.99M | (3.5M) | 19.19M | (14.5M) | (13.4M) |
| Other Working Capital | 27.49M | 2.3M | 3.53M | 11.51M | 399.41M |
| Other Non-Cash Items | 97.74M | 83.8M | 109.21M | 26.63M | 48.03M |
| Operating Cash Flow | 102.54M | 69.9M | 74.91M | 183.04M | 254.3M |
| Capital Expenditures | (25.48M) | (26.5M) | (34.98M) | (47.11M) | (81.1M) |
| Acquisitions (Net) | 41.25M | (8.9M) | 0 | 0 | 0 |
| Purchases of Investments | (3.65M) | (3M) | (6.5M) | (1.14M) | (5.7M) |
| Sales of Investments | 23.06M | 88K | 0 | 0 | 6.5M |
| Other Investing Activities | 1.73M | (88K) | 1.15M | 89K | 7.4M |
| Investing Cash Flow | 36.9M | (38.4M) | (40.33M) | (48.16M) | (72.9M) |
| Debt Repayment | (487.85M) | 284.01M | 26.4M | 87.97M | (280.93M) |
| Common Stock Issued | 309.62M | 0 | 0 | 0 | 35K |
| Common Stock Repurchased | (12.94M) | (8.7M) | (7.5M) | (8.44M) | (4.43M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.69M | 4.8M | 2.59M | (60.98M) | (378K) |
| Financing Cash Flow | (181.48M) | 280.1M | 21.48M | 18.55M | (285.7M) |
| Effect of Forex Changes | (2.81M) | (4M) | 6.19M | (7.75M) | 16.2M |
| Net Change in Cash | (44.84M) | 307.6M | 62.25M | 145.68M | (88M) |
| Free Cash Flow | 77.07M | 43.4M | 39.93M | 135.93M | 173.2M |
LivaNova PLC
NASDAQ:LIVN
Intrinsic Alpha fair value
Locked
Current Price
$94.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.